NPCE

Neuropace Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↓ 4/10
  • Momentum↑ 5/10
Neuropace sales and earnings growth
NPCE Growth
Neutral
  • Revenue Y/Y↑ 24.08%
  • EPS Y/Y↑ 24.24%
  • FCF Y/Y↓ 1.24%
Neuropace gross and profit margin trends
NPCE Profitability
Neutral
  • Gross margin ↑ 76.80%
  • EPS margin↓ -25.30%
  • ROIC↓ -11.50%
Neuropace net debt vs free cash flow
NPCE Risk
Poor
  • Debt / Equity↑ 3.8
  • Debt / FCF↓ 3.0
  • Interest coverage↓ -2.0

Neuropace stock volatility is in-line with the overall market. We give it a Poor risk rating.

More Medical Devices stocks ↗